Desferrithiocin analogues and nephrotoxicity

被引:11
作者
Bergeron, Raymond J. [1 ]
Wiegand, Jan [1 ]
McManis, James S. [1 ]
Bharti, Neelam [1 ]
Singh, Shailendra [1 ]
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
关键词
D O I
10.1021/jm8003398
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The syntheses of a series of 4'-O-alkylated (S)-4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methyl-4-thiazole-carboxylic acid and 5'-O-alkylated (S)-4,5-dihydro-2-(2,5-dihydroxyphenyl)-4-methyl-4-thiazoleearboxylic acid ligands are described. Their partition between octanol and water, 109 Pap,, is determined, along with their iron-clearing efficiency (ICE) in both non-iron-overloaded, bile duct-cannulated rodents and in iron-overloaded primates. The ligand-promoted biliary ferrokinetics in rats are described for each of the chelators. Plots of log P-app versus ICE in a rodent model for both the 4'-O-alkylated 2,4-dihydroxy and 5'-O-alkylated 2,5-dihydroxy series produced an inverse parabola plot with r(2) values of 0.97 and 0.81, respectively. The plots indicate an optimum log P-app/ICE relationship. Because of the nature of the data spread in the 4'-O-alkylated 2,4-dihydroxy series, it will be used to help assess the origin of nephrotoxicity in desferrithiocin analogues: is toxicity simply related to lipophilicity, ICE, or a combination of these properties?.
引用
收藏
页码:5993 / 6004
页数:12
相关论文
共 62 条
[41]   Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial [J].
Kersten, MJ ;
Lange, R ;
Smeets, MEP ;
Vreugdenhil, G ;
Roozendaal, KJ ;
Lameijer, W ;
Goudsmit, R .
ANNALS OF HEMATOLOGY, 1996, 73 (05) :247-252
[42]  
Koppenol W.H., 2000, IRON CHELATORS NEW D, P3
[43]  
Lieu Pauline T., 2001, Molecular Aspects of Medicine, V22, P1, DOI 10.1016/S0098-2997(00)00006-6
[44]   METABOLITES OF MICROORGANISMS .193. FERRITHIOCIN [J].
NAEGELI, HU ;
ZAHNER, H .
HELVETICA CHIMICA ACTA, 1980, 63 (06) :1400-1406
[45]   Development of tridentate iron chelators: From desferrithiocin to ICL670 [J].
Nick, H ;
Acklin, P ;
Lattmann, R ;
Buehlmayer, P ;
Hauffe, S ;
Schupp, J ;
Alberti, D .
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (12) :1065-1076
[46]   Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia:: a randomised, double-blind, placebo-controlled, dose-escalation trial [J].
Nisbet-Brown, E ;
Olivieri, NF ;
Giardina, PJ ;
Grady, RW ;
Neufeld, EJ ;
Séchaud, R ;
Krebs-Brown, AJ ;
Anderson, JR ;
Alberti, D ;
Sizer, KC ;
Nathan, DG .
LANCET, 2003, 361 (9369) :1597-1602
[47]   Iron-chelating therapy and the treatment of thalassemia [J].
Olivieri, NF ;
Brittenham, GM .
BLOOD, 1997, 89 (03) :739-761
[48]  
Olivieri NF, 1996, ACTA HAEMATOL-BASEL, V95, P37
[49]   Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major [J].
Olivieri, NF ;
Brittenham, GM ;
McLaren, CE ;
Templeton, DM ;
Cameron, RG ;
McClelland, RA ;
Burt, AD ;
Fleming, KA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07) :417-423
[50]   L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy [J].
Oudit, GY ;
Sun, H ;
Trivieri, MG ;
Koch, SE ;
Dawood, F ;
Ackerley, C ;
Yazdanpanah, M ;
Wilson, GJ ;
Schwartz, A ;
Liu, PP ;
Backx, PH .
NATURE MEDICINE, 2003, 9 (09) :1187-1194